INO
$7.99
Inovio Pharmaceuticals
($.51)
(6.00%)
INO
Earnings Whisper ®
N/A
2nd Quarter June 2015
Consensus:  ($0.04)
Revenue:  N/A
Friday
Aug 7
After the close
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when INO reports earnings?
Beat
Meet
Miss

Where is INO's stock price going from here?
Up
Flat
Down
Stock chart of INO
Analysts
Summary of analysts' recommendations for INO
Score
Grade
Pivots
Resistance
$8.61
$8.48
$8.24

$8.11

Support
$7.87
$7.74
$7.50
Tweet
Growth
Description
Inovio Pharmaceuticals, Inc., formerly known as Inovio Biomedical Corporation, is engaged in the discovery, development, and delivery of a new generation of vaccines, called DNA vaccines, focused on cancers and infectious diseases. The Company's electroporation DNA delivery technology uses brief, controlled electrical pulses to increase cellular DNA vaccine uptake. Inovio's clinical programs include human papillomavirus (HPV)/cervical cancer (therapeutic), avian influenza (preventative), hepatitis C virus (HCV) and human immunodeficiency virus (HIV) vaccines. It is advancing preclinical research for a universal seasonal/pandemic influenza vaccine. The Company's partners and collaborators include University of Pennsylvania, National Microbiology Laboratory of the Public Health Agency of Canada, NIAID, Merck, ChronTech, University of Southampton, and HIV Vaccines Trial Network. Inovio Pharmaceuticals, Inc. is headquartered in Blue Bell, Pennsylvania.
Peers
Biogen IdecGilead SciencesAmgenQiagen N.V.Seattle GeneticsBluebird BioBioCryst PharmaceuticalsNeurocrine BiosciencesARIAD PharmaceuticalsNovavax